Corteva (NYSE:CTVA) Sets New 1-Year High on Analyst Upgrade

Corteva, Inc. (NYSE:CTVA)’s stock price reached a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $89.00 to $95.00. Oppenheimer currently has an outperform rating on the stock. Corteva traded as high as $88.57 and last traded at $88.5550, with a volume of 2140586 shares. The stock had previously closed at $86.94.

Other equities analysts have also recently issued reports about the company. Bank of America boosted their price target on Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Zacks Research upgraded Corteva from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. UBS Group cut their target price on shares of Corteva from $90.00 to $86.00 and set a “neutral” rating for the company in a research note on Tuesday, June 9th. Royal Bank Of Canada upped their target price on shares of Corteva from $97.00 to $103.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Rothschild & Co Redburn raised their price target on shares of Corteva from $80.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $90.19.

Corteva News Roundup

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Oppenheimer raised its price target on Corteva to $95 from $89 and kept an “outperform” rating, signaling confidence in further upside for the stock.
• Positive Sentiment: Zacks upgraded Corteva to Rank #2 (Buy), citing improving earnings prospects ahead of the company’s upcoming results.
• Positive Sentiment: Analysts expect Q2 earnings growth as premium seed demand, new products, and productivity gains help offset pricing and inflation pressure. Corteva Set to Report Q2 Earnings: What Investors Should Expect
• Neutral Sentiment: Corteva declared a quarterly dividend of $0.18 per share, payable September 15 to shareholders of record on September 1, which supports the stock’s income profile but is not a major growth catalyst. Corteva Declares Quarterly Dividend
• Neutral Sentiment: The company is set to report Q2 earnings soon, and investors are awaiting confirmation that demand and operating efficiency trends are holding up. Corteva (CTVA) Projected to Release Quarterly Earnings on Thursday

Institutional Trading of Corteva

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. William B. Walkup & Associates Inc. lifted its holdings in shares of Corteva by 2.9% during the 1st quarter. William B. Walkup & Associates Inc. now owns 4,457 shares of the company’s stock worth $373,000 after acquiring an additional 126 shares during the period. Wilkerson Advisory Group LLC grew its holdings in Corteva by 6.7% in the first quarter. Wilkerson Advisory Group LLC now owns 2,112 shares of the company’s stock valued at $177,000 after purchasing an additional 133 shares during the period. AdvisorNet Financial Inc increased its position in Corteva by 2.4% during the first quarter. AdvisorNet Financial Inc now owns 5,694 shares of the company’s stock worth $477,000 after purchasing an additional 135 shares during the last quarter. First Horizon Corp increased its position in Corteva by 9.2% during the first quarter. First Horizon Corp now owns 1,600 shares of the company’s stock worth $134,000 after purchasing an additional 135 shares during the last quarter. Finally, Aviance Capital Partners LLC raised its stake in Corteva by 1.3% during the first quarter. Aviance Capital Partners LLC now owns 11,008 shares of the company’s stock worth $922,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Stock Performance

The company has a market cap of $59.68 billion, a PE ratio of 52.49, a P/E/G ratio of 2.69 and a beta of 0.56. The stock’s 50 day simple moving average is $81.39 and its two-hundred day simple moving average is $78.91. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07.

Corteva (NYSE:CTVA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.32. The company had revenue of $4.91 billion during the quarter, compared to analysts’ expectations of $4.64 billion. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, research analysts anticipate that Corteva, Inc. will post 3.76 earnings per share for the current year.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Tuesday, September 1st will be given a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, September 1st. Corteva’s payout ratio is 42.35%.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.